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The sonographic quantitative assessment
of the deltoid muscle to detect type 2 diabetes
mellitus: a potential noninvasive and sensitive
screening method?
Kelli A. Rosen1, Anay Thodge1, Amy Tang2, Brendan M. Franz1, Chad L. Klochko1 and Steven B. Soliman1*

Abstract
Background: In our previous published study, we demonstrated that a qualitatively assessed elevation in deltoid
muscle echogenicity on ultrasound was both sensitive for and a strong predictor of a type 2 diabetes (T2DM) diagnosis. This study aims to evaluate if a sonographic quantitative assessment of the deltoid muscle can be used to detect
T2DM.
Methods: Deltoid muscle ultrasound images from 124 patients were stored: 31 obese T2DM, 31 non-obese T2DM, 31
obese non-T2DM and 31 non-obese non-T2DM. Images were independently reviewed by 3 musculoskeletal radiologists, blinded to the patient’s category. Each measured the grayscale pixel intensity of the deltoid muscle and humeral
cortex to calculate a muscle/bone ratio for each patient. Following a 3-week delay, the 3 radiologists independently
repeated measurements on a randomly selected 40 subjects. Ratios, age, gender, race, body mass index, insulin usage
and hemoglobin A1c were analyzed. The difference among the 4 groups was compared using analysis of variance or
chi-square tests. Both univariate and multivariate linear mixed models were performed. Multivariate mixed-effects
regression models were used, adjusting for demographic and clinical variables. Post hoc comparisons were done with
Bonferroni adjustments to identify any differences between groups. The sample size achieved 90% power. Sensitivity
and specificity were calculated based on set threshold ratios. Both intra- and inter-radiologist variability or agreement
were assessed.
Results: A statistically significant difference in muscle/bone ratios between the groups was identified with the average ratios as follows: obese T2DM, 0.54 (P < 0.001); non-obese T2DM, 0.48 (P < 0.001); obese non-T2DM, 0.42 (P = 0.03);
and non-obese non-T2DM, 0.35. There was excellent inter-observer agreement (intraclass correlation coefficient 0.87)
and excellent intra-observer agreements (intraclass correlation coefficient 0.92, 0.95 and 0.94). Using threshold ratios,
the sensitivity for detecting T2DM was 80% (95% CI 67% to 88%) with a specificity of 63% (95% CI 50% to 75%).
Conclusions: The sonographic quantitative assessment of the deltoid muscle by ultrasound is sensitive and accurate for the detection of T2DM. Following further studies, this process could translate into a dedicated, simple and
noninvasive screening method to detect T2DM with the prospects of identifying even a fraction of the undiagnosed
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persons worldwide. This could prove especially beneficial in screening of underserved and underrepresented
communities.
Keywords: Type 2 diabetes mellitus, Diabetes screening, Musculoskeletal ultrasound, Deltoid muscle, Shoulder,
Muscle echogenicity

Background
Type 2 diabetes mellitus (T2DM) affects approximately
463 million adults worldwide, including 34.2 million
or 10.5% of people in the United States (U.S.) [1–3].
The worldwide prevalence is projected to significantly
increase in the coming decades, reaching 700 million by
2045 [1, 4–6]. This disease disproportionately affects the
underserved, underrepresented, impoverished, and lower
socioeconomic communities, as well as those in developing countries [1–3, 7, 8]. These groups account for 79% of
people with T2DM [1–3, 7, 8]. Furthermore, a staggering
232 million or 50% of people with T2DM worldwide and
7.3 million or 21.4% in the U.S. are unaware and undiagnosed [1, 2, 9]. This is secondary to the current screening
methods for T2DM being inconvenient, invasive, poorly
sensitive, and inaccurate [10–14]. Furthermore, when
T2DM is finally detected in a patient, at the time of diagnosis, approximately one-half already have one or more
irreversible complications [15].
Earlier detection of this disease is critical as T2DM
leads to multiple costly serious end-organ complications,
including being the leading cause of both end-stage renal
disease and non-traumatic lower extremity amputations
[1, 3, 5, 16]. Those with T2DM are also at approximately
double the risk of death when compared to those without
the disease [2]. Health expenditure worldwide for treating T2DM in 2019 was at least $760 (U.S. dollars) billion
and in the U.S. alone was estimated at $327 (U.S. dollars)
billion in 2017 [1, 3, 17]. However, once diagnosed, treatment of T2DM with effective blood glucose management
has been shown to have significant health benefits and
even reduce the risk of associated ophthalmologic, renal,
and neurologic diseases by 40% [1, 3, 18–21].
Given its advantages over MRI, musculoskeletal (MSK)
ultrasound (US) utilization, especially at shoulder level,
has significantly increased over the past few decades
[22–25]. Shoulder US is often performed on patients with
T2DM, given the high prevalence of T2DM in society
and the increased risk of rotator cuff pathology and adhesive capsulitis in people with T2DM [26–30]. As shown
in our previously published study, a qualitatively assessed
increased deltoid muscle echogenicity (subjectively elevated grayscale pixel echo intensity [GPEI]) on shoulder US was a strong predictor of T2DM and may prove
useful in its detection [23]. While fatty infiltration of
muscle in obese individuals is known to cause muscular

hyperechogenicity [31–36], our prior study revealed that
both non-obese and obese patients with T2DM manifested a still greater qualitative deltoid muscle GPEI than
what we observed in obese individuals who tested negative for T2DM [23].
Therefore, in this study we aimed to evaluate if our
prior qualitative findings could be validated objectively
using a quantitative assessment of the deltoid muscle
GPEI on US to detect T2DM. We believe that following
further studies, this method could serve as an opportunistic tool in screening for and detecting T2DM with the
hope of identifying some of the 232 million worldwide
undiagnosed people with T2DM. This could prove to be
especially instrumental for screening in underserved and
underrepresented communities worldwide. Earlier detection, lifestyle modifications, and treatment of this disease, through this opportunistic screening method, may
prevent or reduce the known devastating complications
of T2DM and help mitigate a portion of the enormous
healthcare economic burden.

Methods
This study was performed in accordance with the ethical standards of our institutional research committee
and with the 1964 Declaration of Helsinki and its later
amendments or comparable ethical standards. Institutional review board approval was obtained for this retrospective study, and informed consent was waived (Henry
Ford Health System IRB # 13,208, August 22, 2019). Our
study complied with the Health Insurance Portability and
Accountability Act.
Selection of Obese T2DM, Non‑obese T2DM, and Obese
non‑T2DM Cohorts

Using a random number generator, the following
cohorts were randomly selected from a database of
patients that were included in our previously published study [23]: 31 obese patients with T2DM, 31
non-obese patients with T2DM, and 31 obese patients
without T2DM. The criteria for the selection of these
patients are detailed in Table 1. These patients presented between October 2005 and November 2017.
A chart review confirmed the absence of any relevant
history or concomitant diagnoses such as muscle contusion, strain, paralysis, myositis, rhabdomyolysis,
statin-induced myopathy or any other myopathy that
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Table 1 Clinical criteria for patient selection
Cohort

Inclusion Criteria (All Within 3 Months of a Shoulder US)

Obese withT2DM (n = 31)

-Documented diagnosis of T2DM
-HbA1c level > 6.5% (48 mmol/mol)
-Prescribed at least 1 T2DM medication
-BMI ≥ 30 kg/m2

Non-obese with T2DM (n = 31)

Obese without T2DM (n = 31)

Non-obese without T2DM (n = 31)

-Documented diagnosis of T2DM
-HbA1c level > 6.5% (48 mmol/mol)
-Prescribed at least 1 T2DM medication
-BMI < 30 kg/m2
-Never diagnosed with T2DM or prediabetes/IGT
-HbA1c level < 5.7% (39 mmol/mol) or none available
-Never prescribed T2DM medication
-BMI ≥ 30 kg/m2
-Never diagnosed with T2DM or prediabetes/IGT
-HbA1c level < 5.7% (39 mmol/mol) or none available
-Never prescribed T2DM medication
-BMI < 30 kg/m2

BMI body mass index, HbA1c hemoglobin A1c, IGT impaired glucose tolerance, T2DM type 2 diabetes mellitus, US ultrasound

could alter the sonographic appearance of the deltoid muscle. Furthermore, in the non-T2DM cohort,
the chart review confirmed that there were no current or past diabetes-related diagnoses, whether acute
or chronic. In all cohorts and especially in the nonobese T2DM cohort, a type 1 DM diagnosis was also
excluded. Furthermore, in the T2DM cohorts, a documented diagnosis of T2DM was confirmed based on
the American Diabetes Association criteria for the
diagnosis of T2DM. Demographic information of age,
gender, race, body mass index (BMI), insulin usage, and
hemoglobin A1c (HbA1c) level were obtained from chart
review for inclusion in the previous study and were
again recorded.
Selection of non‑obese non‑T2DM cohort

A fourth cohort of 31 non-obese patients without
T2DM with a complaint of shoulder pain and a subsequent shoulder US examination were also randomly
chosen for inclusion in the study. These patients presented between March 2009 and February 2019. The
criteria utilized for the selection of these ‘normal’ subjects are also listed in Table 1.
A chart review was performed to confirm the absence
of any relevant history or concomitant diagnoses such
as muscle contusion, strain, paralysis, myositis, rhabdomyolysis, statin-induced myopathy or any other myopathy that could alter the sonographic appearance of the
deltoid muscle. Also in this cohort, the chart review
confirmed that there were no current or past diabetesrelated diagnoses, whether acute or chronic. Demographic information of age, gender, and race were also
documented for this cohort.

Sonographic examinations

All shoulder US examinations from these 124 patients
were performed by trained dedicated MSK sonographers,
all of whom possess the registered MSK sonographer
(RMSKS) designation through the American Registry for
Diagnostic Medical Sonography (Rockville, MD, USA).
For each patient a complete shoulder US was performed
utilizing a 9-MHz linear transducer (GE LOGIQ E9 unit;
General Electric Company, Milwaukee, WI, USA).
An author not involved in the blinded review of the
images, for each subject, saved a single static long-axis
US image of the deltoid muscle, obtained at the anterior aspect of the supraspinatus tendon, at its insertion on the greater tuberosity of the proximal humerus
(Figs. 1 and 2).
All 124 images were de-identified and, using a random
number generator, assigned a random number. These 124,
individual, de-identified, and randomized images were
then archived into a secured research survey program for
the subsequent image review and measurements.
Blinded image review and inter‑observer measurements

Three MSK radiology fellows who were not involved in
the selection of subjects or review of medical records
independently evaluated the sonographic images quantitatively, utilizing the research survey program. The
radiologists were blinded to all patients’ categories and
histories. For each of the 124 patients, the three radiologists were instructed to independently measure the
GPEI of a region of interest (ROI) of the deltoid muscle
and a ROI of the underlying humeral cortex (Fig. 1). ROI
values were automatically displayed as standard grayscale pixel levels ranging from 0 (black) to 255 (white).
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Fig. 1 Ultrasound of a 68-year-old man without type 2 diabetes
mellitus or obesity. This long-axis sonographic image of the left
deltoid muscle (open arrows) is obtained at the anterior aspect of
the supraspinatus tendon (S), at its insertion at the greater tuberosity
(solid star) of the proximal humerus (H). The 3 circles overlying the
deltoid muscle indicate the location of the grayscale pixel intensity
region of interest measurements that were obtained to calculate the
mean deltoid muscle value. The open star indicates the location of
the single region of interest measurement obtained on the osseous
cortex of the humeral head, near the anatomic neck. Notice the
hypoechoic appearance of the deltoid muscle. The patient had a
body mass index of 24 kg/m2. The calculated ratio (deltoid muscle/
humeral cortex) for this patient was equal to 0.29, consistent with a
non-type 2 diabetes mellitus status
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A hyperechoic deltoid muscle (Fig. 2) results in an
increased GPEI, and therefore, a higher pixel number.
In the deltoid muscle, they were instructed to obtain
3 separate circular ROI measurements, ranging in size
from 0.035 to 0.065 cm2, including only the deltoid muscle, without subcutaneous or subdeltoid/peribursal fat
(Fig. 1). This was done to obtain an accurate representation of the entire deltoid muscle. However, to avoid areas
of artifact, they were instructed to not obtain deltoid
muscle measurements at the periphery of the images.
As opposed to directly measuring only the deltoid
muscle GPEI, the humeral cortex, a second standard
and stable anatomic location, was also measured on the
same static image. This was done to ensure uniformity of
the technical factors by accounting for any subtle sonographic parameter differences in image gain, depth range,
or dynamic range. In regard to the humeral cortex, they
were to obtain a single ROI measurement on the osseous
cortex of the humeral head, along a smooth portion, near
the anatomic neck. The ROI circle was to only include the
bony cortex and to avoid any areas of osseous irregularity, especially along the greater tuberosity (Figs. 1 and 2).
Each of the 3 radiologists obtained these measurements
on all 31 subjects from each of the 4 groups, for a total of
124 patients. These measurements were performed in a
single image review session and automatically stored in
the system.
Intra‑observer measurements

Following a 3-week delay to avoid recall bias, the 3 radiologists independently repeated these measurements in a
single session, on a randomly selected 40 subjects from
the original 124 subjects, to account for intra-observer
variability.
Sample size, power, and ratio calculations

Fig. 2 Ultrasound of a 47-year-old woman with type 2 diabetes
mellitus. This long-axis sonographic image of the right deltoid muscle
(open arrows) image is also obtained at the anterior aspect of the
supraspinatus tendon (S), at its insertion at the greater tuberosity
(solid star) of the proximal humerus (H). Notice the significant,
diffusely hyperechoic (echogenic) appearance of the deltoid muscle.
The patient had a body mass index of 32 kg/m2. The calculated ratio
(deltoid muscle/humeral cortex) for this patient was equal to 0.67,
consistent with a type 2 diabetes mellitus status

Using measurements from each of the 3 radiologists, the
ratio of deltoid muscle ROI to humeral cortex ROI for
each patient was then calculated. The mean of the 3-deltoid muscle GPEI measurements was used as the numerator and the single humeral cortex GPEI measurement
as the denominator (i.e., mean deltoid muscle GPEI/
humeral cortex GPEI). The more hyperechoic the deltoid muscle (higher GPEI), the greater the expected ratio
(Figs. 1 and 2). Sample size was calculated by the use of
Power Analysis and Sample Size Software (PASS 2019)
(NCSS, LLC. Kaysville, Utah, USA). The total sample size
of 124 patients (31 in each group) achieved 90% power
to detect difference among mean ratios using an analysis of variance F-test with a significance level of 0.05 and
assuming a medium effect size of 0.35.
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Statistical analysis

Patients’ baseline characteristics were presented as
mean (standard deviation) for continuous variables
and frequency (percent) for categorical variables. The
difference among the 4 groups was compared using
analysis of variance or chi-square tests. Both univariate and multivariate linear mixed models were performed to examine the group differences in the ratio
values. Multivariate mixed-effects regression models
were also used, adjusting for demographic and clinical
variables, and considering the variability among radiologists. Post hoc comparisons were performed with
Bonferroni adjustments to identify any differences
between groups. Sensitivity, specificity, accuracy, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio were
also calculated based on a set ratio threshold used for
the obese cohorts and a set ratio threshold used for the
non-obese cohorts. Set ratio thresholds were utilized
since our future studies will be aimed at translating
this process into a dedicated, simple, and noninvasive
screening method to detect T2DM. Therefore, set ratio
thresholds were determined using Youden’s J statistic
(index) with a 1:2 weight for specificity and sensitivity,
respectively. This hypothetical method would require
little to no training and optimally not even require an
actual displayed or visualized image. By simply placing
an US transducer on a person’s shoulder, potentially a
dedicated low-cost portable handheld automated US
unit, these automatically calculated ratios would then
be automatically compared to the set ratio thresholds,
depending on the person’s BMI. Subsequently, an automated probability or result would be displayed.

Both inter- and intra-radiologist variability or agreement were assessed using two‐way mixed-effects models
to calculate the intraclass correlation coefficient (ICC)
value for each measurement. All ICC values were interpreted using the Rosner interpretation (0‐0.40: poor
agreement; > 0.40‐0.75: good agreement; and > 0.75‐1.00:
excellent agreement).
All statistical analyses were performed using SAS 9.4
(SAS Institute Inc., Cary, NC, USA). Statistical significance was defined as a P < 0.05.

Results
Study cohorts

Of the 31 obese patients with T2DM, the age range was
34–78 years with a mean age of 60.7. The mean BMI was
38.7 kg/m2 with a range from 31–55 kg/m2.The average
HbA1c level was 7.7% (61 mmol/mol) with a range from
6.9%-11.9% (52–107 mmol/mol). Additional demographic data is listed in Table 2.
Of the 31 non-obese patients with T2DM, the age
range was 49–87 years with a mean age of 65.6. The mean
BMI was 25.6 kg/m2 with a range from 19–29 kg/m2.
The average H
 bA1c level was 7.2% (55 mmol/mol) with a
range from 6.8%-13.6% (51–125 mmol/mol). Additional
demographic data is listed in Table 2.
Of the 31 obese patients without T2DM, the age range
was 18–69 years with a mean age of 36.4. The mean BMI
was 33.9 kg/m2 with a range from 30–49 kg/m2. Additional demographic data is listed in Table 2.
Of the 31 non-obese patients without T2DM, the age
range was 18–76 years with a mean age of 39.6. The mean
BMI was 24.4 kg/m2 with a range from 18–29 kg/m2.
Additional demographic data is listed in Table 2.

Table 2 Patient demographics, BMI, HbA1c, insulin usage, and muscle/bone ratios among the study cohorts
Patient Data

Age, years (mean ± SD)

Obese with T2DM
(n = 31)
60.7 ± 17.6

18 (58.1%)

Non-obese with T2DM
(n = 31)
65.6 ± 18.0

21 (67.7%)

Obese without T2DM
(n = 31)
36.4 ± 17.7

14 (45.2%)

Non-obese
without T2DM
(n = 31)
39.6 ± 17.4

Gender

Female
Male

13 (41.9%)

10 (32.3%)

17 (54.8%)

19 (61.3%)

Race

Black

15 (48.4%)

20 (64.5%)

15 (48.4%)

10 (32.3%)

White

16 (51.6%)

11 (35.5%)

16 (51.6%)

21 (67.7%)

7.7% ± 1.6 (61 mmol/mol) 7.2% ± 1.5 (55 mmol/mol) ――――

BMI, kg/m2 (mean ± SD)

< 0.001
0.01
0.09

―――― 0.23

38.7 ± 2.7

25.6 ± 7.6

17 (54.8%)

11 (35.5%)

――――

―――― 0.13

Average 0.54

0.48

0.42

0.35

Median

0.48

0.41

0.34

HbA1c (mean ± SD)

Insulin usage

33.9 ± 8.8

12 (38.7%)

P-value

24.4 ± 3.0

Muscle/Bone ratio

< 0.001

< 0.001
0.54

BMI body mass index, HbA1c hemoglobin A1c, T2DM type 2 diabetes mellitus

Categorical data is represented as frequency (percent of column). Numerical data is represented as mean ± standard deviation (SD)
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Ratio results and statistical significance

Overall, the deltoid muscle/bone ratio averages and
medians for each group were as follows, respectively:
obese T2DM, 0.54 and 0.54; non-obese T2DM, 0.48
and 0.48; obese non-T2DM, 0.42 and 0.41; and nonobese non-T2DM, 0.35 and 0.34 (Table 2).
These ratio differences demonstrated statistical significance. When compared to the ‘normal’ non-obese
group without T2DM, the obese T2DM ratio was
increased by 0.19 (P < 0.001), the non-obese T2DM was
increased by 0.13 (P < 0.001), and the obese non-T2DM
was increased by 0.07 (P = 0.03).
Following multivariate analysis with adjustments for
age, gender, and race, the ratio differences remained
statistically significant. When compared to the ‘normal’ non-obese group without T2DM, the obese T2DM
ratio was increased by 0.15 (P < 0.001), the non-obese
T2DM was increased by 0.08 (P = 0.04), and the obese
non-T2DM was increased by 0.07 (P = 0.02).
Intra‑ and inter‑observer agreement

There was excellent inter-observer agreement between
all 3 MSK radiology fellows (ICC 0.87 (95% CI 0.81 to
0.92)). Following the 3-week delayed measurements,
there was also excellent intra-observer agreements
(ICC 0.92 (95% CI 0.88 to 0.94), 0.95 (95% CI 0.92 to
0.97), and 0.94 (95% CI 0.90 to 0.96)).
Sensitivity, specificity, positive predictive value,
and negative predictive value

Knowing a patient’s BMI and using a threshold ratio of
greater than approximately 0.43 if obese, and a threshold ratio of greater than approximately 0.36 if nonobese, the sensitivity for detecting T2DM is 80% (95%
CI 67% to 88%) with a specificity of 63% (95% CI 50%
to 75%). The accuracy is equal to 71% (95% CI 62% to
79%). The positive predictive value is 68% (95% CI 60%
to 75%) and the negative predictive value is 75% (95%
CI 64% to 83%). The positive likelihood ratio is 2.13
(95% CI 1.5 to 3) and the negative likelihood ratio is
0.33 (95% CI 0.2 to 0.6).
Moreover, using a threshold ratio of greater than
approximately 0.31 if obese, and a threshold ratio of
greater than approximately 0.33 if non-obese, the sensitivity for detecting T2DM increases to 94% (95% CI 84%
to 98%) with a specificity of 31% (95% CI 20% to 44%).
The positive predictive value is 57% (95% CI 53% to 62%)
and the negative predictive value is 83% (95% CI 63% to
93%). The positive likelihood ratio is 1.35 (95% CI 1.13
to 1.61) and the negative likelihood ratio is 0.21 (95% CI
0.08 to 0.58).
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Effects of demographics, insulin usage, race, and BMI
on ratios

Women, on average, had a 0.1 increase to the ratio
when compared to men, which was statistically significant (P = 0.0036). Insulin users, on average, had a 0.02
increase to the ratio when compared to non-insulin
users, albeit statistically insignificant (P = 0.51). Whites
had a 0.07 increase to the ratio when compared to blacks,
which was statistically significant (P = 0.035).
Furthermore, 1 unit increase of BMI (kg/m2) was associated with only a 0.006 increase to the ratio (P = 0.007).
For example, the difference in mean BMI between the
obese T2DM group and the non-obese group without T2DM is 14.3 kg/m2. This would equate to a ratio
increased by 0.086 in the obese T2DM group, however,
when compared to the non-obese group without T2DM,
the obese T2DM group’s ratio was actually increased by
an astonishing nearly 0.2 (P < 0.001), demonstrating that
there is an additional element elevating these muscle/
bone ratios, out of proportion to the just the influence
of BMI. No significant ratio differences were identified
when using multivariate analysis adjusting for age, gender, race, BMI and HbA1c levels.

Discussion
In our previous study, we demonstrated that a qualitatively assessed elevation in deltoid muscle echogenicity on US was both sensitive for and a strong predictor
of a T2DM diagnosis [23]. In this first study of its kind,
we confirmed that a sonographic quantitative assessment
of the deltoid muscle GPEI, using muscle/bone ratios, is
also sensitive and accurate for the detection of T2DM in
both obese and non-obese cohorts.
Worldwide, an astonishing 232 million or 50% of people with T2DM are undiagnosed, including 7.3 million
in the U.S. alone [1, 2, 9]. Underdiagnosis is especially
prevalent in underserved, underrepresented, impoverished, and lower socioeconomic communities, as well
as developing countries, which account for 79% of those
affected by T2DM [1–3, 7, 8]. Earlier detection of T2DM
is extremely important. If left uncontrolled, T2DM leads
to multiple medically devastating and costly end-organ
complications, and nearly doubles the risk of death [1–
3, 5, 15, 16]. Moreover, medical expenses for treating
T2DM in 2019 worldwide were at least $760 (U.S. dollars) billion, including approximately $327 (U.S. dollars)
billion in the U.S. alone [1, 3, 17].
Current screening methods for T2DM are limited to
blood tests, which may not be ideal since they are invasive and require the use of laboratory analysis that can be
time, labor, and resource intensive. Additionally, phlebotomy, for some individuals, can be a traumatic experience
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that may lead to unnecessary anxiety and side effects such
as ecchymosis, bleeding, vasovagal reactions, skin irritation, and pain. Furthermore, current screening methods
for T2DM are lacking given their poor sensitivities, inaccuracies, inconveniences, and invasiveness [10–14].
As utilization of MSK US increases [22–25], a unique
opportunity arises for detecting T2DM in undiagnosed,
unsuspecting individuals presenting for [seemingly]
unrelated medical care. As published in our prior study,
as a large institution performing a substantial volume of
MSK US and, in particular, shoulder US, it has been our
experience that the incidental detection of a hyperechoic
deltoid muscle has on multiple occasions resulted in the
incidental diagnosis of previously undetected T2DM
[23]. Following further studies, we believe these results
can be translated into a new dedicated, simple, and noninvasive diagnostic screening tool for the detection of
T2DM. This screening tool could result in prevention or
reduction of the devastating T2DM complications and
help reduce the enormous disease-associated economic
burden.
Hypotheses

Although the exact cause of the sonographically
increased muscle/bone ratio in T2DM is uncertain, our
findings, in combination with those of our previous study
[23], offer a few hypotheses. Firstly, given that this ratio
is increased in both obese and non-obese persons with
T2DM, this could relate to excessive adipose muscle
infiltration, out of proportion to the BMI level [34–36].
Stouge and colleagues, in a study utilizing magnetic resonance imaging, demonstrated increased fat accumulation
in the muscles of patients with T2DM [37]. Furthermore,
multiple studies have shown that excess adipose muscle
infiltration (‘myosteatosis’ and ‘muscle lipotoxicity’) is
associated with muscle insulin resistance and can affect
muscle function [38–50]. However, studies performed
on patients with neuromuscular diseases, including muscular dystrophies, have shown that muscle echogenicity
on US can actually decrease with excessive adipose muscle infiltration, likely secondary to decreased acoustic
impedance [51, 52], which would actually decrease the
muscle/bone ratio.
Taking this into consideration, an alternate hypothesis
is that this increased ratio could also relate to decreased
intramuscular glycogen, in addition to excessive adipose
muscle infiltration. It is well known that insulin resistance in T2DM results in impaired insulin-stimulated
intramuscular glycogen synthesis [53, 54]. He and Kelley,
in their study utilizing muscle biopsies of non-obese and
obese patients with and without T2DM, demonstrated
that intramuscular glycogen levels are decreased up to
65% in those with T2DM [55]. Multiple studies have also
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shown that decreased intramuscular glycogen levels in
the postexercise state and in critically ill patients can be
visualized on US as increased muscle echogenicity [23,
56–59] and therefore cause an increase in the muscle/
bone ratio. Further studies are necessary to verify these
potential hypotheses and identify specific causation.
Prediabetes/Impaired glucose tolerance and limitations

The limitations of this study should be acknowledged
when interpreting the results. Firstly, given the retrospective nature of the study, we had an unequal gender and
age representation in each cohort (Table 2). However,
multivariate analysis failed to show any significant ratio
differences when adjusting for age. Nevertheless, a future
prospective investigation, controlling for gender and age,
could be performed. Next, given that intramuscular glycogen depletion in the postexercise state and with dehydration have also been shown to cause a hyperechoic
deltoid muscle [56–58] and, therefore, increase the muscle/bone ratio, lack of awareness of our patients’ exercise
regimen and hydration status is an additional limitation. Another limitation of this study is non-inclusion of
patients with type 1 diabetes and prediabetes (impaired
glucose tolerances [IGT]) patients. A future prospective
study could be performed with the inclusion of both persons with type 1 diabetes and prediabetes/IGT.
Interestingly however, upon a 2-year follow-up
review of the non-T2DM cohort by whom the set
threshold ratios for measuring sensitivity and specificity were labelled as false positives, we found 10 patients
had subsequently developed prediabetes/IGT based on
abnormal HbA1c levels. Using this updated data, our
sensitivity rose to 82%, specificity to 75%, and accuracy to 79% (versus original sensitivity of 80%, specificity of 63%, and accuracy 71%). This not only suggests
that the quantitative method detects prediabetes/
IGT, but also proposes that increased deltoid muscle echogenicity may predate or predict elevation of
HbA1c levels. This is vitally important as prediabetes/
IGT affects a staggering 374 million or 1 in 11 adults
worldwide, including 88 million or 34.5% of adults in
the U.S. [1–3]. Furthermore, an overwhelming 90% of
these patients -more than 79 million in the U.S. aloneare undiagnosed and completely unaware of their prediabetic/IGT status [1, 3], placing them at a very high
risk of developing T2DM [1–3]. It is known that skeletal muscle insulin resistance is the primary defect in
the development of T2DM, often occurring decades
before β-cell failure and apparent metabolic dysfunction [60]. Could these identified US changes represent
the noninvasive detection of early muscle insulin resistance and dysfunction, prior to clinically apparent metabolic dysfunction? Is US offering us an inexpensive,
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noninvasive window into the development and natural history of prediabetes/IGT and developing T2DM?
And, is US identifying early muscle insulin resistance
[60], prior to elevation of HbA1c levels? If further studies can confirm these hypotheses and validate the use of
this screening method for prediabetes/IGT, this would
prove extremely beneficial, as earlier lifestyle modifications have been shown to reduce the risk of developing
T2DM by greater than 50% [1, 3, 18–21, 61, 62].

Availability of data and materials
The anonymized datasets used and/or analyzed during the current study are
available from the corresponding author on reasonable request.

Conclusion
In conclusion, our study demonstrates that a sonographic
quantitative assessment of the deltoid muscle is both
sensitive and accurate for the detection of T2DM. This
method could be used during shoulder US as a supplemental opportunistic tool aiding in earlier detection of
T2DM in patients who may otherwise go undiagnosed.
Following further studies, this process could translate
into a dedicated, simple, and noninvasive screening
method to detect T2DM with the prospects of identifying even a fraction of the 232 million undiagnosed persons with T2DM and potentially the hundreds of millions
of undiagnosed persons with prediabetes/IGT worldwide. This could prove especially beneficial in screening of underserved and underrepresented communities,
as well as developing countries. Earlier diagnosis and
therefore earlier treatment, may prevent or reduce the
devastating complications of T2DM and help mitigate a
portion of the enormous disease-associated healthcare
economic burden.
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